<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04189783</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0780</org_study_id>
    <secondary_id>NCI-2019-07564</secondary_id>
    <secondary_id>2019-0780</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT04189783</nct_id>
  </id_info>
  <brief_title>Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients (&quot;RESQU-SARC&quot; Trial)</brief_title>
  <official_title>Randomized Controlled Trial of Repeat vs. Single Quadratus Lumborum Block to Reduce Opioid Prescriptions After Open Resection of Retroperitoneal Sarcoma (&quot;RESQU-SARC&quot; Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well a repeat or single liposomal bupivacaine injection&#xD;
      (quadratus lumborum block) works in reducing opioid prescriptions after surgery in patients&#xD;
      with retroperitoneal sarcoma. Liposomal bupivacaine is a numbing medication. Giving a second&#xD;
      injection block may decrease dependency on opioid medications for pain relief after surgery&#xD;
      and prevent long-term use and addiction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To use a pragmatic phase II randomized controlled trial to compare two standardized&#xD;
      bundles of usual care for postoperative pain management to reduce the initial discharge&#xD;
      prescription opioid volume.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To assess which pragmatic arm improves aspects of postoperative recovery including 30-day,&#xD;
      3-month, and 1-year opioid use, patient symptom inventory at those time points, hospital&#xD;
      measures including length of stay and inpatient pain scores.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients receive standard of care liposomal bupivacaine injection before and during&#xD;
      surgery and standard of care non-opioids and opioids at days 0-3 after surgery in the absence&#xD;
      of unacceptable toxicity.&#xD;
&#xD;
      ARM II: Patients receive standard of care liposomal bupivacaine injection before and during&#xD;
      surgery and standard of care non-opioids and opioids at days 0-3 after surgery in the absence&#xD;
      of unacceptable toxicity. Patients then receive a second liposomal bupivacaine injection on&#xD;
      day 4 after surgery.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 1, 3, and 12 months after&#xD;
      the surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Initial discharge prescription oral morphine equivalents (OME)</measure>
    <time_frame>At time of discharge (median of 9 days)</time_frame>
    <description>Will perform two-sample t-test to compare the mean doses of discharge prescription OME between the two groups. In addition, multiple linear regression analysis will be carried out to assess the difference between the two arms after adjusting for the stratification factors and other patient characteristics at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with zero discharge prescription OME</measure>
    <time_frame>At time of discharge (median of 9 days)</time_frame>
    <description>Logistic regression analyses will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes for gastrointestinal surgery</measure>
    <time_frame>Up to 12 months post surgery</time_frame>
    <description>Will be captured using MD Anderson Symptom Inventory-Gastrointestinal (MDASI-GI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily inpatient pain scores</measure>
    <time_frame>At time of discharge (median of 9 days)</time_frame>
    <description>Linear mixed model will be used for continuous outcomes such as daily inpatient pain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total length of stay</measure>
    <time_frame>At time of discharge (median of 9 days)</time_frame>
    <description>Will perform two-sample t-test to compare the total length of stay between the two groups. In addition, multiple linear regression analysis will be carried out to assess the difference between the two arms after adjusting for the stratification factors and other patient characteristics at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day total OME</measure>
    <time_frame>At 30 days after discharge</time_frame>
    <description>Will perform two-sample t-test to compare the 30-day total OME between the two groups. In addition, multiple linear regression analysis will be carried out to assess the difference between the two arms after adjusting for the stratification factors and other patient characteristics at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Initial discharge pain prescription dosage/size</measure>
    <time_frame>At time of discharge (median of 9 days)</time_frame>
    <description>Will perform two-sample t-test to compare the initial discharge pain prescription dosage/size between the two groups. In addition, multiple linear regression analysis will be carried out to assess the difference between the two arms after adjusting for the stratification factors and other patient characteristics at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of postoperative days until zero opioid use</measure>
    <time_frame>Up to 12 months post surgery</time_frame>
    <description>Will perform two-sample t-test to compare the number of postoperative days until zero opioid use between the two groups. In addition, multiple linear regression analysis will be carried out to assess the difference between the two arms after adjusting for the stratification factors and other patient characteristics at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid use at 30 days</measure>
    <time_frame>At 30 days post surgery</time_frame>
    <description>Logistic regression analyses will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid use at 3 months</measure>
    <time_frame>At 3 months post surgery</time_frame>
    <description>Logistic regression analyses will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid use at 12 months</measure>
    <time_frame>At 12 months post surgery</time_frame>
    <description>Logistic regression analyses will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDASI-GI at 30 days</measure>
    <time_frame>At 30 days post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDASI-GI at 3 months</measure>
    <time_frame>At 3 months post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MDASI-GI at 12 months</measure>
    <time_frame>At 12 months post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients free of opioid use</measure>
    <time_frame>At 3 months post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients free of opioid use</measure>
    <time_frame>Up to 1 year post surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Retroperitoneal Sarcoma</condition>
  <arm_group>
    <arm_group_label>Arm I (liposomal bupivacaine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive standard of care liposomal bupivacaine injection before and during surgery and standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (liposomal bupivacaine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive standard of care liposomal bupivacaine injection before and during surgery and standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity. Patients then receive a second liposomal bupivacaine injection on day 4 after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Bupivacaine</intervention_name>
    <description>Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity</description>
    <arm_group_label>Arm I (liposomal bupivacaine)</arm_group_label>
    <arm_group_label>Arm II (liposomal bupivacaine)</arm_group_label>
    <other_name>Bupivacaine Liposome Injectable Suspension</other_name>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quadratus Lumborum Block</intervention_name>
    <description>Patients receive standard of care liposomal bupivacaine injection before and during surgery, followed by standard of care non-opioids and opioids at days 0-3 after surgery in the absence of unacceptable toxicity. Patients receive a second liposomal bupivacaine injection (&quot;RESQU&quot; block) on day 4 after surgery</description>
    <arm_group_label>Arm I (liposomal bupivacaine)</arm_group_label>
    <arm_group_label>Arm II (liposomal bupivacaine)</arm_group_label>
    <other_name>QL Block</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (liposomal bupivacaine)</arm_group_label>
    <arm_group_label>Arm II (liposomal bupivacaine)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing elective open sarcoma resection for potentially curative intent&#xD;
             who would otherwise be treated with quadratus lumborum (QL) block +&#xD;
             intravenous-patient controlled analgesia (IV-PCA) converted to oral pain medications&#xD;
             (meds) (non-narcotic bundle + opioid pain pill)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with current or past substance (drug or alcohol) abuse disorder&#xD;
&#xD;
          -  Laparoscopic or minimally invasive surgery&#xD;
&#xD;
          -  Cases in which anticipated discharge is on or before postoperative day 4&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Scally</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher Scally</last_name>
    <phone>713-792-6940</phone>
    <email>cpscally@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher P. Scally</last_name>
      <phone>713-792-6940</phone>
    </contact>
    <investigator>
      <last_name>Christopher P. Scally</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>December 3, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2019</study_first_posted>
  <last_update_submitted>August 4, 2020</last_update_submitted>
  <last_update_submitted_qc>August 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

